Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy

[1]  A. Rigby,et al.  Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.

[2]  A. Rigby,et al.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. , 2017, Journal of the American College of Cardiology.

[3]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[4]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[5]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[6]  T. Chao,et al.  Rate-Control Treatment and Mortality in Atrial Fibrillation , 2015, Circulation.

[7]  G. Fonarow,et al.  Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) , 2015, Journal of the American Heart Association.

[8]  S. Solomon,et al.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. , 2015, European heart journal.

[9]  F. Edelmann,et al.  Heart rate following short‐term beta‐blocker titration predicts all‐cause mortality in elderly chronic heart failure patients: insights from the CIBIS‐ELD trial , 2014, European journal of heart failure.

[10]  A. Hallas,et al.  Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. , 2014, International journal of cardiology.

[11]  John G F Cleland,et al.  Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.

[12]  H. Crijns,et al.  Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study , 2013, European journal of heart failure.

[13]  A. Jacobson,et al.  Heart rate control in patients with chronic atrial fibrillation and heart failure. , 2013, Congestive heart failure.

[14]  J. Cleland,et al.  Heart rate achieved or beta‐blocker dose in patients with chronic heart failure: which is the better target? , 2012, European journal of heart failure.

[15]  K. Swedberg,et al.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[16]  S. Anker,et al.  Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. , 2012, International journal of cardiology.

[17]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[18]  Jeroen J. Bax,et al.  Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. , 2012, European heart journal.

[19]  K. Swedberg,et al.  Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study , 2012, Clinical Research in Cardiology.

[20]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[21]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[22]  M. Gold,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2011 .

[23]  M. Cheitlin.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2011 .

[24]  Michael Böhm,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.

[25]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[26]  H. Krum,et al.  Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure? , 2010, Cardiovascular therapeutics.

[27]  Michael Böhm,et al.  Heart rate reduction in cardiovascular disease and therapy , 2010, Clinical Research in Cardiology.

[28]  B. Fagerberg,et al.  The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). , 2009, Journal of cardiac failure.

[29]  P. Armstrong,et al.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. , 2009, Annals of internal medicine.

[30]  C. O'connor,et al.  Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). , 2008, The American journal of cardiology.

[31]  B. Billah,et al.  Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. , 2008, The American journal of cardiology.

[32]  C. Pepine,et al.  Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.

[33]  A. Remppis,et al.  Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy , 2008, Clinical Research in Cardiology.

[34]  M. Komajda,et al.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey , 2007, European journal of heart failure.

[35]  L. Køber,et al.  Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes , 2007, Circulation.

[36]  J. Butler,et al.  Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction? , 2006, Congestive heart failure.

[37]  H. Strömer,et al.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the Mahler survey. , 2006, European heart journal.

[38]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[39]  S. Gottlieb,et al.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). , 2005, Journal of the American College of Cardiology.

[40]  H. Krumholz,et al.  Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. , 2004, Archives of internal medicine.

[41]  C. Coffey,et al.  Adverse effects of -blocker therapy for patients with heart failure: A quantitative overview of ran , 2004 .

[42]  M. Fowler.  Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. , 2004, The American journal of cardiology.

[43]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[44]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[45]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[46]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[47]  M. Brignole,et al.  Is sinus bradycardia a factor facilitating overt heart failure? , 1999, European heart journal.

[48]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[49]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[50]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[51]  W. French,et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.

[52]  R. Fraser.  [Clinical research in cardiology in Canada]. , 1962, L'union medicale du Canada.